CORRECTION: Shares of Myriad Genetics Move Lower as Co. Reports Launch of myRisk Hereditary Cancer Panel

Myriad Genetics, Inc.(Nasdaq: MYGN) announced today that it has launched myRisk Hereditary Cancer, anew multi-gene diagnostic test that will provide increased sensitivity byanalyzing 25 genes associated with eight major cancers including: breast,colorectal, ovarian, endometrial, pancreatic, prostate, gastric and melanoma.myRisk Hereditary Cancer is being launched in a phased approach beginning withan early-access, clinical-experience program to a limited number of medicaland scientific thought leaders followed by an expanded access program later inthe year. The Company will present extensive clinical validity data for myRiskHereditary Cancer at The Collaborative Group of the Americas on InheritedColorectal Cancer (CGA) annual meeting in October and the San Antonio BreastCancer Symposium in December.The new myRisk Hereditary Cancer test represents the next generation ofhereditary cancer testing and will provide healthcare providers with clear andactionable information to improve patient care, regardless of whether thepatient receives a positive or negative test result. Each test report willinclude a genetic test result, a clinical risk and healthcare management toolbased on professional society guidelines.